Today: 30 June 2026
Browse Category

NYSE:NHI 8 November 2025

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 08.11.2025

{“@context”:”https://schema.org”,”@type “:”LiveBlogPosting”,”@id”:”https://ts2.tech/en/stock-market-today-08-11-2025/#live”,”headline”:”Stock Market Today 08.11.2025″,”description”:”Live rolling coverage of technology news: AI, chips, gadgets, software, startups, cybersecurity, telecom, and policy.”,”datePublished”:”2025-11-08T00:00:00-05:00″,”dateModified”:”2025-11-09T00:00:03-05:00″,”coverageStartTime”:”2025-11-08T00:00:00-05:00″,”coverageEndTime”:”2025-11-09T00:00:03-05:00″,”author”:{“@type”:”Organization”,”name”:”TechStock²”},”publisher”:{“@type”:”Organization”,”name”:”TechStock²”,”logo”:{“@type”:”ImageObject”,”url”:”https://ts2.tech/wp-content/uploads/2024/02/cropped-ts2-logo-google.png”}},”inLanguage”:”en-US”,”liveBlogUpdate”:[{“@type”:”BlogPosting”,”@id”:”https://ts2.tech/en/stock-market-today-08-11-2025/#live/u/2314de997ba25bfa”,”headline”:”National Health Investors Valuation Check: Is NHI Still Undervalued After Momentum?”,”articleBody”:”National Health Investors (NHI) has advanced about 4% in the last month, yielding a three-year total return near 60% while the one-year return remains flat, signaling mixed sentiment. With shares at $76.80 and a fair value call of $83.14, a valuation gap persists that could pave upside if SHOP expansion drives earnings. The note highlights potential for outsized multi-year NOI and earnings growth, but warns that near-term risks include occupancy softness and
8 November 2025

Stock Market Today

  • Telix Pharmaceuticals (ASX:TLX) tops Australian growth stocks with large insider holdings
    June 30, 2026, 3:11 AM EDT. Telix Pharmaceuticals (ASX:TLX) is at the front of Australian growth stocks with high insider ownership, seen as a sign of management confidence. The biopharma group, focused on radiopharmaceuticals in cancer imaging and care, pulled in about US$803.8 million in sales, most of that coming from the U.S. The company's market cap stands at A$5.5 billion. Telix's cancer pipeline is broad, and its commercial footing is firm. Its key products, Illuccix and Gozellix, support 2026 revenue targets of US$950-970 million. There's still risk from regulatory and pricing pressure, but insiders remain aligned, and partnerships with United Imaging and Regeneron support the growth story. Also mentioned: Lindian Resources (ASX:LIN), market cap A$1.7 billion, which is pushing ahead on a rare earths project in Malawi. Both names show that shareholder interest tracks with insider backing.
Go toTop